Athos Therapeutics Reports Promising Phase 1 Results for AI-Developed ATH-063

Athos Therapeutics unveiled positive Phase 1 clinical trial data for ATH-063, an innovative AI-generated oral G9A inhibitor. ATH-063 increased circulating regulatory T cells and enriched genes linked to anti-inflammatory activities. The trial, involving 76 healthy volunteers, evaluated safety, pharmacokinetics (PK), and pharmacodynamics (PD) through various dosing methods. No severe side effects were observed, and the drug displayed favorable PK results.

The trial confirmed ATH-063's mechanism, showcasing Tregs' selective activation and significant increase, aligning with Athos' AI2 predictions. Furthermore, the drug correlated with reduced levels of IBD biomarkers. Athos plans to advance ATH-063 to address ulcerative colitis, confident in the AI2 platform's efficacy in drug development.